Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048

Clinical Infectious Diseases(2020)10.1093/cid/ciaa368Source: DataRank Database

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 is a research paper published in Clinical Infectious Diseases (2020). On theSindex it has a DataRank of 1.6. It has been cited 56 times, with 39 citing works in its 1-hop citation network.

N/A

1.6DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access56 citations · 39 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02783820 NCT02783833

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 5.62)OA: hybridTopics (48)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 39%Citation Network 61%

Base Score Contribution

0.606

From this paper's citation signal

Citation Network Contribution

0.958

From 33 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 39 citers.

Integration and application of new approach methodologies in assessing the developmental hazards: Case study with an antimalarial drug
Birth Defects Research20236 citations14 referencesContributes 0.139
Application of Vinamidinium Salt Chemistry for a Palladium Free Synthesis of Anti-Malarial MMV048: A “Bottom-Up” Approach
Organic Letters202114 citations23 referencesContributes 0.118
Volunteer infection studies accelerate the clinical development of novel drugs against malaria
The Lancet Infectious Diseases20221 citations7 referencesContributes 0.099
PI4‐kinase and PfCDPK7 signaling regulate phospholipid biosynthesis in Plasmodium falciparum
EMBO Reports202117 citations43 referencesContributes 0.067
Efficacy of the Antimalarial MMV390048 against Babesia Infection Reveals Phosphatidylinositol 4-Kinase as a Druggable Target for Babesiosis
Antimicrobial Agents and Chemotherapy202211 citations38 referencesContributes 0.065

Authors (11)

Cristina Donini ORCID,Stephan Chalon ORCID,John Woodford ORCID,Louise Marquart ORCID,Katharine A. Collins ORCID

Live enrichment

PubMed:32239164 PMC:PMC7744986 OpenAlex:https://openalex.org/W3015151532

National Institutes of Health

Grant: R01 AI109023

Wellcome Trust

Grant: unidentified

unidentified

National Institutes of Health

Grant: 1R01AI109023-01A1

Defining P. falciparum resistance to artemisinin-based combination therapies

National Health and Medical Research Council

Department for International Development, UK Government

Medicines for Malaria Venture

Direktoratet for Utviklingssamarbeid

Irish Aid

Newcrest Mining

Bill and Melinda Gates Foundation

United States Agency for International Development

Wellcome Trust

FWCI

5.62

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://academic.oup.com/cid/article-pdf/71/10/e657/34933174/ciaa368.pdf

publisherhttps://academic.oup.com/cid/article-pdf/71/10/e657/34933174/ciaa368.pdf

publisherhttp://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa368/33373619/ciaa368.pdf

publisherhttp://academic.oup.com/cid/article-pdf/71/10/e657/34933174/ciaa368.pdf

journalhttps://doi.org/10.1093/cid/ciaa368

Fields of Study

Malaria Research and ControlTrypanosoma species research and implicationsMultiple Myeloma Research and Treatments03 medical and health sciences0302 clinical medicine

MeSH Terms

AdultAminopyridinesAntimalarialsDose-Response Relationship, DrugDouble-Blind MethodHumansPlasmodiumSulfonesVolunteersMalaria, Falciparum1-Phosphatidylinositol 4-Kinase

Keywords

MedicinePharmacokineticsPharmacodynamicsPlaceboPharmacologyVolunteerAdverse effectRandomized controlled trialInternal medicineBiologySafetyAntimalarialMmv390048Plasmodium Phosphatidylinositol 4-KinaseAdultVolunteersPlasmodium610Radboud University Medical CenterAminopyridines2726 Microbiology (medical)AntimalarialsDouble-Blind Method615HumansSulfonesMalaria, FalciparumOnline Only Articles1-Phosphatidylinositol 4-KinaseRadboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life SciencesDose-Response Relationship, Drug2725 Infectious Diseases

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048

FAIR Checklist

DataRank Breakdown

Top 5 citers driving the network score

Authors (11)

Funding (12 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)